Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

By C. Sternberg, I. Davis, J. Mardiak, C. Szczylik, Eunsik Lee, J. Wagstaff, C. Barrios, P. Salman, O. Gladkov, A. Kavina and 6 more. Journal of Clinical Oncology, 2010

2,439 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6052ac9789d4e5078b73ba302ea89a081c598321

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Adamis
2. W. Marston Linehan
3. Charles Swanton
4. Eric E. Schadt
5. A. Robles
6. Huanhuan Chen
7. Li-li Zheng
8. Zhenling Liu

In Molecular Biology

1. Alexey I. Nesvizhskii
2. A. Adamis
3. Dmitry Avtonomov
4. Andy T. Kong
5. N. Ferrara
6. W. Marston Linehan
7. Charles Swanton
8. Eric E. Schadt

In Pulmonary and Respiratory Medicine

1. Arul M. Chinnaiyan
2. Charles Swanton
3. N. Ferrara
4. Rakesh K. Jain

Citations in the corpus

• Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma (2019, background): “Current first-line therapies for advanced ccRCC target VEGF and mTOR (Escudier et al., 2007a, 2007b; Hudes et al., 2007; Motzer et al., 2007, 2008; Sternberg et al., 2010), with ongoing exploration of immune checkpoint inhibitors (Atkins and Tannir, 2018).”
• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Three vascular endothelial growth factor (VEGF)-targeted agents have demonstrated efficacy in pivotal phase III trials, mostly focused on good and intermediate patients: bevacizumab (combined with IFN), sunitinib and pazopanib [41-43].”
• Cabozantinib versus everolimus in advanced renal cell carcinoma (2015, neutral): “Peripheral edema 31 (9) 0 72 (22) 5 (2)”
• EAU guidelines on renal cell carcinoma: 2014 update. (2010, neutral): “2 mo) [45].”
• Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “Three vascular endothelial growth factor (VEGF)-targeted agents have demonstrated efficacy in pivotal phase III trials, mostly focused on good and intermediate patients: bevacizumab (combined with IFN), sunitinib and pazopanib [41-43].”
• Pazopanib versus sunitinib in metastatic renal-cell carcinoma. (2013, neutral): “Increased blood thyrotropin 31 (6) 0 0 66 (12) 0 0”
• Systemic therapy in metastatic renal cell carcinoma (2016, background): “Pazopanib was not inferior to sunitinib in a phase 3 study and sunitinib proved to be superior to IFN-α [16, 18].”
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, methodology): “413,414 Pazopanib was firstly enrolled in clinical treatment by FDA for patients with advanced RCC on a basis of a randomized and double-blind phase III trial (NCT00334282), in which PFS rate was increased five months compared with placebo.(415) However, the advantage of pazopanib was not shown in p”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “…in pancreatic endocrine cells — could potentially benefit from anti-angiogenic therapy 118 Monotherapy with the VEGFR RTKI pazopanib has proved efficacious in locally advanced or metastatic renal cell carcinoma 120 (TABLE 1) , and it exhibits an improved safety profile compared with sunitinib 121 .”
• Renal cell carcinoma (2017, background): “Three vascular endothelial growth factor (VEGF)-targeted agents have demonstrated efficacy in pivotal phase III trials, mostly focused on good and intermediate patients: bevacizumab (combined with IFN), sunitinib and pazopanib [41-43].”